Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).
1 finding from 1 review
HR 1.05 [0.99, 1.12]
Studies not reported
Moderate
Overall survival ‐ Gemcitabine plus other agent(s) · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus platinum agent · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (calculated instead of overall survival)
The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus fluoropyrimidine · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus topoisomerase inhibitor · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus other combinations of chemotherapy · advanced pancreatic cancer
Gemcitabine combinations may leads to lower overall survival ‐ Gemcitabine plus other combinations of chemotherapy compared with gemcitabine alone (low certainty).
1 finding from 1 review
Intervention not reported
year overall survival in patients of good performance status (WHO performance status 0‐1) · adults with non small cell lung cancer who are not felt to be curable
1 finding from 1 review
Intervention not reported
year overall survival in patients of poor performance status (WHO performance status 2‐4) · adults with non small cell lung cancer who are not felt to be curable
The intervention showed no clear difference in year overall survival in patients of poor performance status (WHO… (moderate certainty).
1 finding from 1 review
Overall survival: higher‐dose WBRT vs control (3000 cGy/10 daily fractions)No. of participants: 846(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher overall survival: lower‐dose WBRT vs control WBRT (3000 cGy/10 daily… compared with WBRT control (moderate certainty).
2 findings from 1 review
HR 1.21 [1.04, 1.4]
Studies not reported
Moderate
HR 0.97 [0.83, 1.12]
Studies not reported
Moderate
Overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT (2000 cGy/4‐5 daily fractions)No. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in overall survival: WBRT 4000 cGy/20 fractions BID vs control WBRT… compared with WBRT control (moderate certainty).
1 finding from 1 review
HR 1.18 [0.89, 1.56]
Studies not reported
Moderate
Intervention not reported
Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
1 finding from 1 review